CORONA Remedies Acquires 7 Pharma Brands from Bayer India

The acquisition strengthens CORONA’s prescription portfolio in India, enhancing presence in key therapeutic segments.

CORONA Remedies Buys 7 Pharma Brands from Bayer India
info_icon

 CORONA Remedies on Thursday said it has acquired seven brands from the pharmaceutical division of Bayer in India for an undisclosed sum.

The acquisition includes brands in the cardiology segment (Noklot) and women's healthcare portfolio (Fostine, Luprofact, Menodac, Ovidac, Spye and Vageston) in the Indian market, the company said in a statement.

Through the acquisition, the company said it is entering the anti-platelet monotherapy segment while also increasing presence in the cardiology domain.

Big Bets On Small Nuclear

31 October 2025

Get the latest issue of Outlook Business

amazon
Published At:
SUBSCRIBE
Tags

Click/Scan to Subscribe

qr-code

Advertisement

Advertisement

Advertisement

Advertisement

×